GAIN Begins (Part 1): FDA Completes Turnaround On Antibiotic R&D
This article was originally published in RPM Report
In less than two years, FDA has moved from requiring unrealistic approval standards for antibiotics to exploring innovative ways to shorten the pathway for the most-needed drugs. And, surprise: Congress is on board too. After 15 years, there is finally real momentum on antibiotic drug policy. But is it all enough to get companies back in the game?
You may also be interested in...
US FDA Joins Chorus Of Concerns About Results Of GAIN Act
It's too early to say whether program is working, FDA tell Congress; agency has awarded 147 QIDP designations, but none of 12 approved antibacterals have new mechanism of action.
Better Incentives Needed For Worsening Fungal Infection Threat
The increasing threat of treatment-resistant Candida auris fungal infections suggests the need for greater development incentives, CEOs of three antifungal drug developers told the recent BIO annual meeting.
Anti-Infective Incentives: GAIN, LPAD Won’t Be Enough HHS-Commissioned Report Finds
The continuing government interest in incentives for antibacterial development got a boost from an unexpected quarter in June. A report commissioned by HHS calls for a broad package of incentives to stimulate continued investment in new anti-infectives.